Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07318103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 32 days later Jul 2026 → Sep 2026
See other at-risk trials from Fujian Shengdi Pharmaceutical Co., Ltd.

Record History

  1. Primary completion pushed from Jul 2026 to Sep 2026 Completion pushed from Aug 2026 to Oct 2026 · Eligibility criteria expanded, about 15 words Show 2 more changesShow less
    • Completion pushed from Aug 2026 to Oct 2026
    • Eligibility criteria expanded, about 15 words
  2. Eligibility criteria shortened, about 74 wordsv4 See this version in full on ClinicalTrials.gov ↗
  3. Enrollment increased: 118 → 153 participants Interventions: 5% Glucose Injection (Drug), HRS-9057 injection set (Drug) to 5% Glucose Injection or 0.9% sodium chloride injection (Drug), HRS-9057 injection set (Drug) · Eligibility criteria shortened, about 53 wordsv3 Show 2 more changesShow less
    • Interventions: 5% Glucose Injection (Drug), HRS-9057 injection set (Drug) to 5% Glucose Injection or 0.9% sodium chloride injection (Drug), HRS-9057 injection set (Drug)
    • Eligibility criteria shortened, about 53 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 2026 to Dec 31, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jan 2026 to Dec 31, 2025
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention
Trial Details
NCT Number NCT07318103
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Fluid Retention Caused by Heart Failure
Enrollment 153 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov